{"pmid":32349111,"title":"COVID-19 Pandemic: Ways Forward.","text":["COVID-19 Pandemic: Ways Forward.","Asia Pac J Ophthalmol (Phila)","Wong, Raymond L M","Lai, Kenny H W","Huang, Suber S","Jonas, Jost B","Lam, Dennis S C","32349111"],"journal":"Asia Pac J Ophthalmol (Phila)","authors":["Wong, Raymond L M","Lai, Kenny H W","Huang, Suber S","Jonas, Jost B","Lam, Dennis S C"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32349111","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1097/APO.0000000000000283","weight":0,"_version_":1665441658266714113,"score":8.599203,"similar":[{"pmid":32249257,"title":"Macrolide treatment for COVID-19: Will this be the way forward?","text":["Macrolide treatment for COVID-19: Will this be the way forward?","The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic that has developed in late 2019 and 2020 is a serious threat to human health. With no vaccines or drugs approved for prevention and treatment until now, all efforts at drug design and/or clinical trials of already approved drugs are worthy and creditable. Using structure-based drug selection for identification of SARS-CoV-2 protease inhibitors, old drugs such as macrolides (MAC) were predicted to be effective for COVID-19. Lately, the anti-viral effects of macrolides have attracted considerable attention. Very recently, hydroxychloroquine in combination with azithromycin treatment was reported to be effective for COVID-19. We believe that treatments with macrolides alone or in combination with other drugs are promising and open the possibility of an international strategy to fight this emerging viral infection.","Biosci Trends","Ohe, Masashi","Shida, Haruki","Jodo, Satoshi","Kusunoki, Yoshihiro","Seki, Masahide","Furuya, Ken","Goudarzi, Houman","32249257"],"abstract":["The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic that has developed in late 2019 and 2020 is a serious threat to human health. With no vaccines or drugs approved for prevention and treatment until now, all efforts at drug design and/or clinical trials of already approved drugs are worthy and creditable. Using structure-based drug selection for identification of SARS-CoV-2 protease inhibitors, old drugs such as macrolides (MAC) were predicted to be effective for COVID-19. Lately, the anti-viral effects of macrolides have attracted considerable attention. Very recently, hydroxychloroquine in combination with azithromycin treatment was reported to be effective for COVID-19. We believe that treatments with macrolides alone or in combination with other drugs are promising and open the possibility of an international strategy to fight this emerging viral infection."],"journal":"Biosci Trends","authors":["Ohe, Masashi","Shida, Haruki","Jodo, Satoshi","Kusunoki, Yoshihiro","Seki, Masahide","Furuya, Ken","Goudarzi, Houman"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32249257","week":"202015|Apr 06 - Apr 12","doi":"10.5582/bst.2020.03058","keywords":["COVID-19","SARS-CoV-2","macrolide"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Macrolides","Hydroxychloroquine","Azithromycin"],"_version_":1663352136202715136,"score":85.66489},{"pmid":32317500,"title":"Coronavirus and ophthalmology: What do we know and way forward.","text":["Coronavirus and ophthalmology: What do we know and way forward.","Indian J Ophthalmol","Khanna, Rohit C","32317500"],"journal":"Indian J Ophthalmol","authors":["Khanna, Rohit C"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317500","week":"202017|Apr 20 - Apr 26","doi":"10.4103/ijo.IJO_834_20","source":"PubMed","weight":0,"_version_":1664815087807889410,"score":85.29084},{"pmid":32240618,"title":"Screening faecal microbiota transplant donors for SARS-CoV-2 by molecular testing of stool is the safest way forward.","text":["Screening faecal microbiota transplant donors for SARS-CoV-2 by molecular testing of stool is the safest way forward.","Lancet Gastroenterol Hepatol","Green, Christopher A","Quraishi, Mohammed N","Shabir, Sahida","Sharma, Naveen","Hansen, Richard","Gaya, Daniel R","Hart, Ailsa L","Loman, Nicholas J","Iqbal, Tariq H","32240618"],"journal":"Lancet Gastroenterol Hepatol","authors":["Green, Christopher A","Quraishi, Mohammed N","Shabir, Sahida","Sharma, Naveen","Hansen, Richard","Gaya, Daniel R","Hart, Ailsa L","Loman, Nicholas J","Iqbal, Tariq H"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32240618","week":"202014|Mar 30 - Apr 05","doi":"10.1016/S2468-1253(20)30089-3","source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664638354290900992,"score":58.265823},{"pmid":32348012,"title":"COVID-19: looking forward.","text":["COVID-19: looking forward.","Intern Med J","Szer, Jeff","32348012"],"journal":"Intern Med J","authors":["Szer, Jeff"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32348012","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/imj.14865","topics":["General Info"],"weight":1,"_version_":1665441658256228352,"score":54.34945},{"pmid":32303841,"title":"Lead the way or leave the way: leading a Department of Orthopedics through the COVID-19 pandemic.","text":["Lead the way or leave the way: leading a Department of Orthopedics through the COVID-19 pandemic.","Eur J Orthop Surg Traumatol","Mauffrey, Cyril","Trompeter, Alex","32303841"],"journal":"Eur J Orthop Surg Traumatol","authors":["Mauffrey, Cyril","Trompeter, Alex"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303841","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s00590-020-02670-x","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664632934622035968,"score":48.3419}]}